Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Hang Su(307th Hospital of Chinese People’s Liberation Army), Yongping Song(Zhengzhou University), Wenqi Jiang(Sun Yat-sen University Cancer Center), Xiuhua Sun(Dalian Medical University), Wenbin Qian(First Affiliated Hospital Zhejiang University), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuhuan Gao(Hebei Medical University), Zhengming Jin(Soochow University), Jianfeng Zhou(Huazhong University of Science and Technology), Chuan Jin(Guangzhou Medical University), Liqun Zou(Sichuan University), Lugui Qiu(Institute of Hematology & Blood Diseases Hospital), Wei Li(Jilin University), Jianmin Yang(Changhai Hospital), Ming Hou(Qilu Hospital of Shandong University), Shan Zeng(Xiangya Hospital Central South University), Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Jianda Hu(Union Hospital), Hui Zhou, Yan Xiong, Peng Liu(Chinese Academy of Medical Sciences & Peking Union Medical College)
The Lancet Haematology
January 1, 2019
Cited by 244

Abstract


Related Papers

No related papers found

Powered by citation graph analysis